AU2002224875A1 - Modulation of the interaction between evh1 domains - Google Patents

Modulation of the interaction between evh1 domains

Info

Publication number
AU2002224875A1
AU2002224875A1 AU2002224875A AU2487502A AU2002224875A1 AU 2002224875 A1 AU2002224875 A1 AU 2002224875A1 AU 2002224875 A AU2002224875 A AU 2002224875A AU 2487502 A AU2487502 A AU 2487502A AU 2002224875 A1 AU2002224875 A1 AU 2002224875A1
Authority
AU
Australia
Prior art keywords
modulation
interaction
evh1 domains
evh1
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224875A
Inventor
Peter Druckes
Thomas Jarchau
Birgit Jordan
Ulrich Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Verinos Operations GmbH
Original Assignee
Vasopharm Biotech GmbH
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Biotech GmbH, Aventis Pharma Deutschland GmbH filed Critical Vasopharm Biotech GmbH
Publication of AU2002224875A1 publication Critical patent/AU2002224875A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002224875A 2000-11-25 2001-11-22 Modulation of the interaction between evh1 domains Abandoned AU2002224875A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10058596.5 2000-11-25
DE10058596A DE10058596A1 (en) 2000-11-25 2000-11-25 Method of screening chemical compounds for modulating the interaction of an EVH1 domain or a protein with an EVH1 domain with an EVH1 binding domain or a protein with an EVH1 binding domain, and a method for detecting said interaction
PCT/EP2001/013592 WO2002042777A2 (en) 2000-11-25 2001-11-22 Modulation of the interaction between evh1 domains

Publications (1)

Publication Number Publication Date
AU2002224875A1 true AU2002224875A1 (en) 2002-06-03

Family

ID=7664666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224875A Abandoned AU2002224875A1 (en) 2000-11-25 2001-11-22 Modulation of the interaction between evh1 domains

Country Status (6)

Country Link
US (1) US7563582B2 (en)
EP (1) EP1405079B1 (en)
JP (1) JP4437003B2 (en)
AU (1) AU2002224875A1 (en)
DE (1) DE10058596A1 (en)
WO (1) WO2002042777A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100478689C (en) * 2002-08-30 2009-04-15 肿瘤疗法科学股份有限公司 Polypeptide and use thereof
CN106442441B (en) * 2016-09-06 2019-04-02 中国科学院南京地理与湖泊研究所 The method in chromophoric dissolved organic matter source is determined based on fluorescence spectrum integral ratio
CN110058015A (en) * 2019-04-08 2019-07-26 深圳优普生物技术有限公司 The measuring method and application of reagent, kit, platelet response index
CN110135354B (en) * 2019-05-17 2022-03-29 武汉大势智慧科技有限公司 Change detection method based on live-action three-dimensional model

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
FI100276B (en) 1996-02-06 1997-10-31 Orion Yhtymae Oy Method for non-competitive determination of analytes
ES2257756T3 (en) * 1996-03-12 2006-08-01 Sanofi-Aventis Deutschland Gmbh NEW PROPHARMS FOR THERAPY OF TUMORS AND INFLAMMATORY DISEASES.
WO1998001755A1 (en) 1996-07-05 1998-01-15 Fred Hutchinson Cancer Research Center Screening method for mena protein involved in microfilament dynamics
FI963989A (en) 1996-10-04 1998-04-05 Wallac Oy Homogeneous methods of determination based on the transmission of luminescence energy
WO2001074858A2 (en) 2000-04-03 2001-10-11 Massachusetts Institute Of Technology Methods for altering t cell activation
DE10029210A1 (en) 2000-06-14 2002-01-31 Vasopharm Biotech Gmbh & Co Kg Test system and its use

Also Published As

Publication number Publication date
EP1405079A2 (en) 2004-04-07
WO2002042777A3 (en) 2004-01-15
EP1405079B1 (en) 2012-05-30
US20020136717A1 (en) 2002-09-26
JP2004536277A (en) 2004-12-02
DE10058596A1 (en) 2002-06-06
US7563582B2 (en) 2009-07-21
JP4437003B2 (en) 2010-03-24
WO2002042777A2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AU2002213467A1 (en) Modulation of ccr4 function
AU2001294926A1 (en) Antisense modulation of smad6 expression
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2001229363A1 (en) Antisense modulation of caspase 3 expression
AU2001273423A1 (en) Liquid applicator
AU2001239971A1 (en) Antisense modulation of parp expression
AU2002213466A1 (en) Compounds and methods for modulating ccr4 function
ZA200206318B (en) Modulation of bone formation.
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU7876900A (en) Antisense modulation of fra-1 expression
AU3339500A (en) Ferroelectric modulator
AU2001259434A1 (en) Calcitonin-related molecules
AU2001274523A1 (en) Liquid applicator
AU2001271426A1 (en) Modulation of apoptosis
AU2001287136A1 (en) Antisense modulation of glioma-associated oncogene-1 expression
AU2001280588A1 (en) Methods of modulating angiogenesis
AU2001227848A1 (en) Antisense modulation of caspase 8 expression
AU2001289068A1 (en) Antisense modulation of caspase 2 expression
AU4696899A (en) Modulating platelet function
AU2002224875A1 (en) Modulation of the interaction between evh1 domains
AU2001292489A1 (en) Voltage controlled oscillator
AU5522300A (en) Nanometer-scale modulation
EP1368891B8 (en) Iq modulator
AU2002213431A1 (en) Modulation of gene expression using localization domains
AU2002328209A1 (en) Hierarchical modulation